** Shares of drug developer Vigil Neuroscience VIGL.O rise 10% to $2.25
** VIGL says its experimental Alzheimer's drug, VG-3927, reduced key biomarker sTREM2 by up to 50% in cerebral spinal fluid in early-stage trial
** Reduction in sTREM2 levels is expected to help slow progression of Alzheimer's disease, as higher levels suggest brain inflammation
** Co says VG-3927 was well-tolerated and has favorable pharmacokinetic and pharmacodynamic profile in the trial
** VIGL plans to advance into mid-stage trial in Q3 2025
** 8 of 9 brokerages rate stock "buy" or higher and 1 "sell"; their median PT is $16.50 - data compiled by LSEG
** VIGL fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。